Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 5.86 is 17% below its 5-year average of 7.02, around the middle of its 5-year range (1.32–15.62).
As of the fiscal period ended Tuesday, June 30, 2026. 29.89% above its 12-month average of 4.51.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.86.
QUICK RATIO (ACID-TEST)
5.86
QUICK RATIO (ACID-TEST) AVG TTM
4.51
QUICK RATIO (ACID-TEST) AVG 3Y
4.75
QUICK RATIO (ACID-TEST) AVG 5Y
7.02
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+29.89%
CURRENT VS 3Y AVG
+23.44%
CURRENT VS 5Y AVG
-16.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.15
median of 685 covered companies
CURRENT VS SECTOR MEDIAN
+86.01%
vs the sector median at left
Invivyd, Inc.
Market Cap
$248.32M
Quick Ratio (Acid-Test)
5.86
TTM Avg
4.51
3Y Avg
4.75
5Y Avg
7.02
Market Cap
$248.50M
Quick Ratio (Acid-Test)
10.14
TTM Avg
15.36
3Y Avg
19.42
5Y Avg
27.25
Market Cap
$245.38M
Quick Ratio (Acid-Test)
1.54
TTM Avg
1.17
3Y Avg
19.33
5Y Avg
29.22
Market Cap
$242.35M
Quick Ratio (Acid-Test)
0.10
TTM Avg
1.46
3Y Avg
1.56
5Y Avg
2.73
Market Cap
$243.48M
Quick Ratio (Acid-Test)
2.69
TTM Avg
2.01
3Y Avg
1.61
5Y Avg
1.29
Market Cap
$242.34M
Quick Ratio (Acid-Test)
1.35
TTM Avg
1.13
3Y Avg
1.14
5Y Avg
1.18
Market Cap
$256.22M
Quick Ratio (Acid-Test)
8.28
TTM Avg
3.73
3Y Avg
7.03
5Y Avg
8.20
Market Cap
$240.31M
Quick Ratio (Acid-Test)
4.70
TTM Avg
7.13
3Y Avg
7.51
5Y Avg
5.59
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $248.32M | 5.86 | 4.51 | 4.75 | 7.02 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $248.50M | 10.14 | 15.36 | 19.42 | 27.25 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $245.38M | 1.54 | 1.17 | 19.33 | 29.22 |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | 0.10 | 1.46 | 1.56 | 2.73 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.48M | 2.69 | 2.01 | 1.61 | 1.29 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $242.34M | 1.35 | 1.13 | 1.14 | 1.18 |
| InflaRx N.V. (IFRX)vs › | $242.30M | 8.22 | 4.35 | 5.50 | 5.94 |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | 8.28 | 3.73 | 7.03 | 8.20 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.31M | 4.70 | 7.13 | 7.51 | 5.59 |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.42M | 3.19 | 3.85 | 4.21 | 4.14 |
Quick Ratio
5.86
Excludes inventory
Current Ratio
5.87
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 5.86 |
| 2026-03-31 | 5.67 |
| 2025-12-31 | 7.24 |
| 2025-09-30 | 2.47 |
| 2025-06-30 | 1.32 |
| 2025-03-31 | 1.52 |
| 2024-12-31 | 1.62 |
| 2024-09-30 | 1.58 |
| 2024-06-30 | 4.57 |
| 2024-03-31 | 5.77 |
| 2023-12-31 | 4.47 |
| 2023-09-30 | 10.08 |
| 2023-06-30 | 9.54 |
| 2023-03-31 | 15.62 |
| 2022-12-31 | 15.06 |
| 2022-09-30 | 9.14 |
| 2022-06-30 | 7.09 |
| 2022-03-31 | 5.80 |
| 2021-12-31 | 9.94 |
| 2021-09-30 | 12.58 |
| 2021-06-30 | 10.45 |
| 2021-03-31 | 3.31 |
| 2020-12-31 | 8.98 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
